A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

NCT06108544 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1108

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: TAK-279
DRUG: Placebo
DRUG: Apremilast

Sponsor

Takeda